↓ Skip to main content

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Overview of attention for article published in Journal for Immunotherapy of Cancer, May 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 X users

Citations

dimensions_citation
76 Dimensions

Readers on

mendeley
86 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
Published in
Journal for Immunotherapy of Cancer, May 2018
DOI 10.1186/s40425-018-0337-7
Pubmed ID
Authors

Lillian Sun, Pauline Funchain, Jung Min Song, Patricia Rayman, Charles Tannenbaum, Jennifer Ko, Michael Mcnamara, C. Marcela Diaz-Montero, Brian Gastman

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 86 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 14%
Student > Bachelor 10 12%
Student > Master 9 10%
Student > Ph. D. Student 7 8%
Other 5 6%
Other 11 13%
Unknown 32 37%
Readers by discipline Count As %
Medicine and Dentistry 19 22%
Biochemistry, Genetics and Molecular Biology 10 12%
Immunology and Microbiology 7 8%
Agricultural and Biological Sciences 6 7%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Other 5 6%
Unknown 36 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2018.
All research outputs
#16,681,672
of 26,017,215 outputs
Outputs from Journal for Immunotherapy of Cancer
#2,741
of 3,487 outputs
Outputs of similar age
#202,670
of 345,995 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#36
of 40 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. This one is in the 33rd percentile – i.e., 33% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,487 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,995 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.